As the human genome has been mapped and understanding of genetic markers increases, opportunities to tailor treatment for specific patients and groups of patients should grow exponentially.  Turning this vision into reality will require coordinated efforts in both the diagnostic and pharmaceutical arenas However, the question can be asked as to which is more valuable – the test that identifies a patient’s condition or the treatment that alleviates or eliminates the condition.  This conference looks into how life sciences firms are partnering, merging, acquiring and/or competing in response and will delve into the discussion of value in the healthcare system and how it could/should be divided.